More than 214,000 shares have been purchased by the insiders of this biotech in the past three months. The shares are trading a very price, reflecting the company’s turnaround status.
MannKind Corporation (MNKD)
From Nate’s Notes
My Top Stock Pick for 2018 is MannKind Corporation (MNKD). After receiving a very positive label change for its lead product, Afrezza (an inhalable form of insulin), late in 2017, MannKind also raised a sizable chunk of cash and has been putting that money to work running television ads in a number of select regions around the country as part of a campaign to raise awareness of the product among both Type1 and Type2 diabetics.
The company got a new CEO in May, and though there is still plenty of work to be done (insulin is a tough market to crack into!), the story is starting to look more and more like the sort of turnaround story that Wall Street likes to get excited about (and with roughly one-third of the float currently sold short, things could get interesting in a hurry, once awareness of the product finally hits “critical mass” among doctors and diabetics). MNKD is considered a strong buy under $5 and a buy under $10.
Nate Pile, Nate’s Notes, www.NotWallStreet.com, 707-433-7903, December 22, 2017